Internal mouthpiece designs as a future perspective for enhanced aerosol deposition. Comparative results for aerosol chemotherapy and aerosol antibiotics

International Journal of Pharmaceutics

Volumn 456, Issue 2, 2013, Pages 325-331

  Zarogoulidis, Paul ^a,b   Petridis, Dimitris ^c   Ritzoulis, Christos ^c   Darwiche, Kaid ^b   Kioumis, Ioannis ^a   Porpodis, Konstantinos ^a   Spyratos, Dionysios ^a   Hohenforst Schmidt, Wolfgang ^d   Yarmus, Lonny ^e   Huang, Haidong ^f   Li, Qiang ^f   Freitag, Lutz ^b   Zarogoulidis, Konstantinos ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c ALEXANDER TECHNOLOGICAL EDUCATIONAL INSTITUTE OF THESSALONIKI   (Greece)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f II Military University Hospital   (China)

Author keywords

Aerosol; Designs; Mouthpiece

Indexed keywords

ANTIBIOTIC AGENT; BAGALIN; BEGALIN; CARBOPLATIN; CEFEPIME; CEFTAZIDIME; CISPLATIN; DOCETAXEL; GEMCITABINE; HOSPIRA; MAXIPINE; MEROPENEM; PACLITAXEL; PIPERACILLIN; UNCLASSIFIED DRUG; ZOBACTAM;

AEROSOL; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY DEVICE; EQUIPMENT DESIGN; LIGHT SCATTERING; MOUTHPIECE; NEBULIZER; PARTICLE SIZE; PRIORITY JOURNAL;

AEROSOL; AZTREONAM (PUBCHEM CID: 5742832); CARBOPLATIN (PUBCHEM CID: 10339178); CIPROFLOXACIN (PUBCHEM CID: 2764); CISPLATIN (PUBCHEM CID: 84093); DESIGNS; DOCETAXEL (PUBCHEM CID: 148124); DOXORUBICIN (PUBCHEM CID: 31703); GEMCITABINE (PUBCHEM CID: 60750); GENTAMYCIN (PUBCHEM CID: 3467); MOUTHPIECE; PACLITAXEL (PUBCHEM CID: 36314); TOBRAMYCIN (PUBCHEM CID: 36294);

AEROSOLS; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; EQUIPMENT DESIGN; FORECASTING;

EID: 84886722925     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.09.004     Document Type: Article

References (44)

1. A. Ari, O.T. Atalay, R. Harwood, M.M. Sheard, E.A. Aljamhan, and J.B. Fink Influence of nebulizer type, position, and bias flow on aerosol drug delivery in simulated pediatric and adult lung models during mechanical ventilation Respir. Care 55 2010 845 851
2. T.H. Baron, P.S. Kamath, and R.D. McBane Management of antithrombotic therapy in patients undergoing invasive procedures N. Engl. J. Med. 368 2013 2113 2124
3. E.B. Berg, and R.J. Picard In vitro delivery of budesonide from 30 jet nebulizer/compressor combinations using infant and child breathing patterns Respir. Care 54 2009 1671 1678
4. C. Bosquillon Drug transporters in the lung-do they play a role in the biopharmaceutics of inhaled drugs? J. Pharm. Sci. 99 2010 2240 2255
5. B. Boyd, P. Noymer, K. Liu, J. Okikawa, D. Hasegawa, S. Warren, G. Taylor, E. Ferguson, J. Schuster, S. Farr, and I. Gonda Effect of gender and device mouthpiece shape on bolus insulin aerosol delivery using the AERx pulmonary delivery system Pharm. Res. 21 2004 1776 1782 (Pubitemid 39390088)
6. M.M. Clay, D. Pavia, S.P. Newman, and S.W. Clarke Factors influencing the size distribution of aerosols from jet nebulisers Thorax 38 1983 755 759 (Pubitemid 13019505)
7. M.S. Coates, H.K. Chan, D.F. Fletcher, and H. Chiou Influence of mouthpiece geometry on the aerosol delivery performance of a dry powder inhaler Pharm. Res. 24 2007 1450 1456 (Pubitemid 46988211)
8. K. Darwiche, P. Zarogoulidis, N.K. Karamanos, K. Domvri, E. Chatzaki, T.C. Constantinidis, S. Kakolyris, and K. Zarogoulidis Efficacy versus safety concerns for aerosol chemotherapy in non-small-cell lung cancer: a future dilemma for micro-oncology Future Oncol. 9 2013 505 525
9. S.S. Davis, and M.D. Bubb Physico-chemical studies on aerosol solutions for drug delivery 3-The effect of relative humidity on the particle size of inhalation aerosols International Journal of Pharmaceutics 1978 303 314 (Pubitemid 9050662)
10. M.L. Everard, A.R. Clark, and A.D. Milner Drug delivery from jet nebulisers Arch. Dis. Child 67 1992 586 591
11. G.N. Foust, W.A. Potter, M.D. Wilons, and E.B. Golden Shortcomings of using two jet nebulizers in tandem with an aerosol face mask for optimal oxygen therapy Chest 99 1991 1346 1351
12. D.E. Geller, M.W. Konstan, J. Smith, S.B. Noonberg, and C. Conrad Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety Pediatr. Pulmonol. 42 2007 307 313 (Pubitemid 46608898)
13. K.W. Harris, T.G. O'Riordan, and G.C. Smaldone Aerosolized iloprost customized for the critically ill Respir. Care 52 2007 1507 1509
14. D. Heng, S.H. Lee, W.K. Ng, H.K. Chan, J.W. Kwek, and R.B. Tan Novel alternatives to reduce powder retention in the dry powder inhaler during aerosolization Int. J. Pharm. 452 2013 194 200
15. W. Hohenforst-Schmidt, P. Zarogoulidis, K. Darwiche, T. Vogl, E.P. Goldberg, H. Huang, M. Simoff, Q. Li, R. Browning, F.J. Turner, P. Le Pivert, D. Spyratos, K. Zarogoulidis, S.I. Celikoglu, F. Celikoglu, and J. Brachmann Intratumoral chemotherapy for lung cancer: re-challenge current targeted therapies Drug Des. Devel. Ther. 7 2013 571 583
16. D.S. Hui, B.K. Chow, L.C. Chu, S.S. Ng, S.D. Hall, T. Gin, and M.T. Chan Exhaled air and aerosolized droplet dispersion during application of a jet nebulizer Chest 135 2009 648 654
17. L. Jiang, Y. Tang, H. Zhang, X. Lu, X. Chen, and J. Zhu Importance of powder residence time for the aerosol delivery performance of a commercial dry powder inhaler Aerolizer((R)) J. Aerosol. Med. Pulm. Drug Deliv. 25 2012 265 279
18. A.H. Kendrick, E.C. Smith, and J. Denyer Nebulizers-fill volume, residual volume and matching of nebulizer to compressor Respir. Med. 89 1995 157 159
19. A.H. Kendrick, E.C. Smith, and R.S. Wilson Selecting and using nebuliser equipment Thorax 52 Suppl 2 1997 S92 S101
20. N.R. Labiris, and M.B. Dolovich Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications Br. J. Clin. Pharmacol. 56 2003 588 599 (Pubitemid 37491710)
21. N.R. Labiris, and M.B. Dolovich Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications Br. J. Clin. Pharmacol. 56 2003 600 612 (Pubitemid 37491711)
22. C.L. Lin, M.H. Tawhai, G. McLennan, and E.A. Hoffman Characteristics of the turbulent laryngeal jet and its effect on airflow in the human intra-thoracic airways Respir. Physiol. Neurobiol. 157 2007 295 309 (Pubitemid 46777492)
23. H.L. Lin, R.D. Restrepo, D.S. Gardenhire, and J.L. Rau Effect of face mask design on inhaled mass of nebulized albuterol, using a pediatric breathing model Respir. Care 52 2007 1021 1026
24. M.M. Mansour, and G.C. Smaldone Respiratory source control versus receiver protection: impact of facemask fit J. Aerosol. Med. Pulm. Drug Deliv. 26 2013 131 137
25. V.A. Mayercik, A.W. Eller, and M.S. Pihlblad Fungal endophthalmitis developing in asthmatic individuals treated with inhaled corticosteroids Arch. Ophthalmol. 129 2011 952 953
26. S. Miura, S. Watanabe, K. Sato, M. Makino, O. Kobayashi, H. Miyao, A. Iwashima, M. Okajima, J. Tanaka, H. Tanaka, H. Kagamu, A. Yokoyama, I. Narita, and H. Yoshizawa The efficacy of triplet antiemetic therapy with 0.75 mg of palonosetron for chemotherapy-induced nausea and vomiting in lung cancer patients receiving highly emetogenic chemotherapy Support Care Cancer 21 2013 2575 2581
27. S.P. Newman, P.G. Pellow, M.M. Clay, and S.W. Clarke Evaluation of jet nebulisers for use with gentamicin solution Thorax 40 1985 671 676 (Pubitemid 15229602)
28. K. Nikander, L. Agertoft, and S. Pedersen Breath-synchronized nebulization diminishes the impact of patient-device interfaces (face mask or mouthpiece) on the inhaled mass of nebulized budesonide J. Asthma 37 2000 451 459
29. C.W. Park, X. Li, F.G. Vogt, D. Hayes Jr., J.B. Zwischenberger, E.S. Park, and H.M. Mansour Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols Int. J. Pharm. 2013
30. S. Sangwan, B.K. Gurses, and G.C. Smaldone Facemasks and facial deposition of aerosols Pediatr. Pulmonol. 37 2004 447 452 (Pubitemid 38620068)
31. V.L. Silkstone, S.A. Corlett, and H. Chrystyn Relative lung and total systemic bioavailability following inhalation from a metered dose inhaler compared with a metered dose inhaler attached to a large volume plastic spacer and a jet nebuliser Eur. J. Clin. Pharmacol. 57 2002 781 786 (Pubitemid 34143335)
32. E.C. Smith, J. Denyer, and A.H. Kendrick Comparison of twenty three nebulizer/compressor combinations for domiciliary use Eur. Respir. J. 8 1995 1214 1221
33. W. Smits, and G. Desmet Computational fluid dynamics study of the optimal design and operating conditions of the segmentation ring used in parallel segmented flow columns J. Chromatogr. A 1294 2013 50 57
34. C. Wynne, V. Harvey, C. Schwabe, D. Waaka, C. McIntyre, and B. Bittner Comparison of subcutaneous and intravenous administration of Trastuzumab: a Phase I/Ib trial in healthy male volunteers and patients With HER2-positive breast cancer J. Clin. Pharmacol. 2013
35. J. Xi, and P.W. Longest Evaluation of a drift flux model for simulating submicrometer aerosol dynamics in human upper tracheobronchial airways Ann. Biomed. Eng. 36 2008 1714 1734
36. P. Zarogouldis, N.K. Karamanos, K. Porpodis, K. Domvri, H. Huang, W. Hohenforst-Schimdt, E.P. Goldberg, and K. Zarogoulidis Vectors for inhaled gene therapy in lung cancer. Application for nano oncology and safety of bio nanotechnology Int. J. Mol. Sci. 13 2012 10828 10862
37. P. Zarogoulidis, E. Chatzaki, K. Porpodis, K. Domvri, W. Hohenforst-Schmidt, E.P. Goldberg, N. Karamanos, and K. Zarogoulidis Inhaled chemotherapy in lung cancer: future concept of nanomedicine Int. J. Nanomedicine 7 2012 1551 1572
38. P. Zarogoulidis, K. Darwiche, W. Hohenforst-Schmidt, H. Huang, Q. Li, L. Freitag, and K. Zarogoulidis Inhaled gene therapy in lung cancer: proof-of-concept for nano-oncology and nanobiotechnology in the management of lung cancer Future Oncol. 9 2013 1171 1194
39. P. Zarogoulidis, E. Eleftheriadou, I. Sapardanis, V. Zarogoulidou, H. Lithoxopoulou, T. Kontakiotis, N. Karamanos, G. Zachariadis, M. Mabroudi, A. Zisimopoulos, and K. Zarogoulidis Feasibility and effectiveness of inhaled carboplatin in NSCLC patients Invest New Drugs 30 2012 1628 1640
40. P. Zarogoulidis, W. Hohenforst-Schmidt, K. Darwiche, L. Krauss, D. Sparopoulou, L. Sakkas, A. Gschwendtner, H. Huang, F.J. Turner, L. Freitag, and K. Zarogoulidis 2-diethylaminoethyl-dextran methyl methacrylate copolymer nonviral vector: still a long way toward the safety of aerosol gene therapy Gene. Ther. 2013
41. P. Zarogoulidis, N.K. Karamanos, K. Porpodis, K. Domvri, H. Huang, W. Hohenforst-Schmidt, E.P. Goldberg, and K. Zarogoulidis Vectors for inhaled gene therapy in lung cancer. Application for nano oncology and safety of bio nanotechnology Int. J. Mol. Sci. 13 2012 10828 10862 Int J Mol Sci 13, 17290-17291
42. P. Zarogoulidis, I. Kioumis, C. Ritzoulis, D. Petridis, K. Darwiche, K. Porpodis, D. Spyratos, S. Parrish, R. Browning, Q. Li, J.F. Turner, L. Freitag, and K. Zarogoulidis New insights in the production of aerosol antibiotics. Evaluation of the optimal aerosol production system for ampicillin-sulbactam, meropenem, ceftazidime, cefepime and piperacillin-tazobactam Int. J. Pharm. 2013
43. P. Zarogoulidis, N. Papanas, G. Kouliatsis, D. Spyratos, K. Zarogoulidis, and E. Maltezos Inhaled insulin: too soon to be forgotten? J. Aerosol. Med. Pulm. Drug Deliv. 24 2011 213 223
44. P. Zarogoulidis, D. Petridis, C. Ritzoulis, K. Darwiche, D. Spyratos, H. Huang, E.P. Goldberg, L. Yarmus, Q. Li, L. Freitag, and K. Zarogoulidis Establishing the optimal nebulization system for paclitaxel, docetaxel, cisplatin, carboplatin and gemcitabine: back to drawing the residual cup Int. J. Pharm. 453 2013 480 487